Despite significant advances in LC-MS based technologies, challenges remain in implementing a proteomics platform for routine clinical applications. These include the needed robustness as well as the sensitivity and dynamic range of detection to both effectively address extremely small tissue samples, for example microdissected or biopsy tissues, or high dynamic range samples, such as blood plasma. Other key components include providing the needed throughput to enable statistically meaningful number of analyses for clinical setting within a robust platform that utilizes effective quantitative approaches for high accuracy and reproducibility. This chapter describes the key components of a nanoLC- MS based technological approach that is designed to target these challenges by virtue of enhancing sensitivity, dynamic range coverage, and throughput, for the generation of robust quantitative measurements in support of clinical studies.
Revised: May 10, 2011 |
Published: January 29, 2008
Citation
Pasa-Tolic L., J.M. Jacobs, W. Qian, and R.D. Smith. 2008.Quantitative Proteomics using Nano-LC with High Accuracy Mass Spectrometry. In Clinical Proteomics: From Diagnosis to Therapy, edited by JE Van Eyk and MJ Dunn. 89-100. Weinheim:Wiley-VCH.PNNL-SA-51867.